The University of Illinois System said on Wednesday that its national COVID-testing unit Shield T3 has announced affordable, gold-standard, pooled saliva-based PCR testing services to universities, K-12 schools and companies for mass and easy testing.
According to the university, the organizations that utilize its covidSHIELD test for their employees or students have the option to collect samples from up to eight people and then test them in a single pool or "batch" using one test, rather than run each sample on its own test.
In addition, the pooled offering is now possible after the U.S. Food & Drug Administration granted the covidSHIELD test emergency use authorization for pooling earlier this month. If the pool is positive, then one or more of the people tested in that pool may be infected, so each sample in that pool is tested individually. Fewer supplies are used and more tests can be run simultaneously, leading to quicker results.
Concurrently, the Shield T3 testing system has a built-in capability for monitoring test results and vaccine compliance via an online dashboard and an ability to display the compliance status in a personal passport/badge application.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses